Novel therapeutic strategies for castration resistant prostate cancer: Inhibition of persistent androgen production and androgen receptor mediated signaling

Journal of Urology

Volumn 185, Issue 3, 2011, Pages 787-794

  Molina, Arturo ^a   Belldegrun, Arie ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

abiraterone; androgens; castration; prostate; prostatic neoplasms

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE ACETATE; AMINOGLUTETHIMIDE; ANDROGEN RECEPTOR; ANTIANDROGEN; BICALUTAMIDE; BMS 641988; CYTOCHROME P450 17; CYTOCHROME P450 INHIBITOR; DEXAMETHASONE; DIETHYLSTILBESTROL; ESTROGEN; FLUTAMIDE; GLUCOCORTICOID; HYDROCORTISONE; KETOCONAZOLE; NILUTAMIDE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; TAK 700; TOK 001; UNCLASSIFIED DRUG;

ANDROGEN DEPRIVATION THERAPY; ANDROGEN SYNTHESIS; ANOREXIA; ASTHENIA; BINDING AFFINITY; CASTRATION; CASTRATION RESISTANT PROSTATE CANCER; CONSTIPATION; DIARRHEA; DISEASE ASSOCIATION; DRUG BINDING; DRUG DOSE ESCALATION; FATIGUE; GENE EXPRESSION; HEADACHE; HUMAN; MAXIMUM TOLERATED DOSE; NAUSEA; NONHUMAN; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POINT MUTATION; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEIZURE; SIGNAL TRANSDUCTION; UPREGULATION; VOMITING;

EID: 79851510026     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2010.10.042     Document Type: Article

References (49)

1. J.S. Lam, J.T. Leppert, and S.N. Vemulapalli Secondary hormonal therapy for advanced prostate cancer J Urol 175 2006 27
2. I.F. Tannock, R. de Wit, and W.R. Berry Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502
3. D.P. Petrylak, C.M. Tangen, and M.H. Hussain Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 2004 1513
4. D.R. Berthold, G.R. Pond, and F. Soban Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX327 study J Clin Oncol 26 2008 242
5. K.J. Pienta, and D. Bradley Mechanisms underlying the development of androgen-independent prostate cancer Clin Cancer Res 12 2006 1665
6. H.I. Scher, and C.L. Sawyers Biology of progressive, castration resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis J Clin Oncol 23 2005 8253
7. G.J. Bubley, M. Carducci, and W. Dahut Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group J Clin Oncol 17 1999 3461
8. H.I. Scher, S. Halabi, and I. Tannock Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group J Clin Oncol 26 2008 1148
9. S.D. Fossa, P.H. Slee, and M. Brausi Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy a phase III study of the European Organization for Research and Treatment of Cancer Genitourinary Group J Clin Oncol 19 2001 62
10. E.J. Small, S. Halabi, and N.A. Dawson Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583) J Clin Oncol 22 2004 1025
11. H. Suzuki, K. Okihara, and H. Miyake Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade J Urol 180 2008 921
12. H.I. Scher, C. Liebertz, and W.K. Kelly Bicalutamide for advanced prostate cancer: the natural versus treated history of disease J Clin Oncol 15 1997 2928
13. W. Kassouf, S. Tanguay, and A.G. Aprikian Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails J Urol 169 2003 1742
14. E.J. Small, M. Meyer, and M.E. Marshall Suramin therapy for patients with symptomatic hormone-refractory prostate cancer results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone J Clin Oncol 18 2000 1440
15. P.W. Kantoff, S. Halabi, and M. Conaway Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study J Clin Oncol 17 1999 2506
16. J.A. Storlie, J.C. Buckner, and G.A. Wiseman Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma Cancer 76 1995 96
17. C.N. Robertson, K.M. Roberson, and G.M. Padilla Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells J Natl Cancer Inst 88 1996 908
18. W.K. Oh, P.W. Kantoff, and V. Weinberg Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer J Clin Oncol 22 2004 3705
19. D.C. Smith, B.G. Redman, and L. Flaherty A phase II trial of oral diethylstilbestrol as a second-line hormonal agent in advanced prostate cancer Urology 52 1998 257
20. W.H. Kruit, G. Stoter, and J.G. Klijn Effect of combination therapy with aminoglutethimide and hydrocortisone on prostate-specific antigen response in metastatic prostate cancer refractory to standard endocrine therapy Anticancer Drugs 15 2004 843
21. W.D. Figg, Y. Liu, and P. Arlen A randomized, phase II trial of ketoconazole plus aledronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases J Urol 173 2005 790
22. E.J. Small, A. Baron, and L. Fippin Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal J Urol 157 1997 1204
23. J. Holzbeierlein, P. Lal, and E. LaTulippe Gene expression of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance Am J Pathol 164 2004 217
24. C.D. Chen, D.S. Welsbie, and C. Tran Molecular determinants of resistance to antiandrogen therapy Nat Med 10 2004 33
25. M.J. Linja, K.J. Savinainen, and O.R. Saramki Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer Cancer Res 61 2001 3550
26. M. Stanbrough, G.J. Bubley, and K. Ross Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer Cancer Res 66 2006 2815
27. C.W. Gregory, R.T. Johnson, and J.L. Mohler Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen Cancer Res 61 2001 2892
28. R. Hu, T.A. Dunn, and S. Wei Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer Cancer Res 69 2009 16
29. C. Puche, M. Jose, and A. Cabero Expression and enzymatic activity of the P450c17 gene in human adipose tissue Eur J Endocrinol 146 2002 223
30. R.B. Montgomery, E.A. Mostaghel, and R. Vessella Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth Cancer Res 68 2008 4447
31. J.A. Locke, L. Fazli, and H. Adomat Androgen levels increase by intrarumoral de novo steroidogenesis during progression of castration-resistant prostate cancer Cancer Res 68 2008 6407
32. J.L. Mohler, C.W. Gregory, and O.H. Ford 3rd The androgen axis in recurrent prostate cancer Clin Cancer Res 10 2004 440
33. E.A. Mostaghel, S.T. Page, and D.W. Lin Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer Cancer Res 67 2007 5033
34. R.J. Auchus The genetics, pathophysiology, and management of human deficiencies of P450c17 Endocrinol Metab Clin North Am 30 2001 101
35. S.E. Barrie, G.A. Potter, and P.M. Goddard Pharmacology of novel steroidal inhibitors of cytochrome P450 (17)alpha (17 alpha-hydroxylase/C17-20 lyase) J Steroid Biochem Mol Biol 50 1994 267
36. Montgomery B, Mostaghel E, Nelson P, et al. Abiraterone suppresses castration resistant human prostate cancer growth in the absence of testicular and adrenal androgens. Presented at American Association for Cancer Research Special Conference: Advances in Prostate Cancer Research, San Diego, California, January 2124, 2009.
37. A. O'Donnell, I. Judson, and M. Dowsett Hormonal impact of the 17alpha -hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer Br J Cancer 90 2004 2317
38. G. Attard, A.H.M. Reid, and T.A. Yap Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven J Clin Oncol 28 2008 4563
39. C.J. Ryan, M.R. Smith, and L. Fong Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole J Clin Oncol 28 2010 1481
40. G. Attard, A.H.M. Reid, and R. A'Hern Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer J Clin Oncol 27 2009 3742
41. C. Ryan, E. Efstathiou, and M. Smith Phase II multicenter study of chemotherapy (chemo)-nave castration resistant prostate cancer (CRPC) not exposed to ketoconazole (keto), treated with abiraterone acetate (AA) plus prednisone J Clin Oncol 27 suppl 2009 15s
42. A.H. Reid, D. Attard, and D. Danila Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate J Clin Oncol 28 2010 1489
43. D.C. Danila, M.J. Morris, and J. de Bono Phase II multicenter study of abiraterone acetate plus prednisone in patients in patients with docetaxel-treated castration-resistant prostate cancer J Clin Oncol 28 2010 1486
44. C.J. Logothetis, S. Wen, and A. Molina Identification of an androgen withdrawal responsive phenotype in castrate resistant prostate cancer (CRPC) patients (pts) treated with abiraterone acetate (AA) J Clin Oncol 26 suppl 2008 5017
45. R. Dreicer, D.B. Agus, and G.R. MacVicar Safety, pharmacokinetics, and efficacy of TAK-700 in castration-resistant metastatic prostate cancer: a phase I/II open label study Genitourin Cancer Symp Proc 89 2010 103
46. T. Vasaitis, A. Belosay, and A. Schayowitz Androgen receptor inactivation ncontributes to antitumor efficacy of 17α-hydroxylase/17,20-lyase inhibitor 3β-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer Mol Cancer Ther 7 2008 2348
47. C. Tran, and N.J. Ouk SmClegg Development of a second-generation antiandrogen for treatment of advanced prostate cancer Science 324 2009 787
48. H.I. Scher, T.M. Beer, and C.S. Higano Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study Lancet 375 2010 1437
49. R.M. Attar, M. Jure-Kunkel, and A. Balog Discovery of BMS-641988: a novel and potent inhibitor of androgen receptor signaling for the treatment of prostate cancer Cancer Res 69 2009 6522